Evidence map›Paper›PMID 35276585›Full record

ArticleParkinsonism & related disorders2022

Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.

Georgia M Parkin, Jody Corey-Bloom, Jeffrey D Long, Chase Snell, Haileigh Smith, Elizabeth A Thomas

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parkinsonism & related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Systematic Review with Meta-Analysis of Biofluid Markers for Huntington's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Pooled it
  2. Fluid and Imaging Biomarkers in Huntington's Disease.Current neurology and neuroscience reports · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.International journal of molecular sciences · 2023
    Review
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Georgia M ParkinDepartment of Epidemiology, University of California Irvine, Irvine, CA, USA; Institute for Interdisciplinary Salivary Bioscience Research, University of California Irvine, Irvine, CA, USA. Electronic address: gparkin@hs.uci.edu.
Jody Corey-BloomDepartment of Neurosciences, University of California San Diego, San Diego, CA, USA.
Jeffrey D LongDepartment of Psychiatry, Department of Biostatistics, University of Iowa, IA, USA.
Chase SnellDepartment of Neurosciences, University of California San Diego, San Diego, CA, USA.
Haileigh SmithDepartment of Neurosciences, University of California San Diego, San Diego, CA, USA.
Elizabeth A ThomasDepartment of Epidemiology, University of California Irvine, Irvine, CA, USA; Institute for Interdisciplinary Salivary Bioscience Research, University of California Irvine, Irvine, CA, USA.
University of California San Diego · USUniversity of California, Irvine · USUniversity of Iowa · US

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
Exploration of salivary huntingtin for biomarker discoveryR21NS111655 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI THOMAS, ELIZABETH A · 2019 to 2020
$425k
NIA NIH HHS P50 AG005131NINDS NIH HHS R21 NS111655
6 · The paper itself

Abstract

introductionThe inclusion of premanifest Huntington's Disease (Pre-HD) subjects in clinical trials necessitates selecting those who are near transition to manifest Huntington's disease (Man-HD). We previously determined that plasma neurofilament light (NfL) levels are significantly correlated with predicted years to Man-HD onset, using established formulae. Recently, a new normalized prognostic index (PIN) score for predicting Pre-HD disease progression has been validated. Our objective was to determine whether plasma NfL levels are similarly associated with PIN score and PIN score-derived years to Man-HD onset (PIN-YTO).

method112 individuals (46 Pre-HD, 66 Man-HD) underwent blood sample collection and clinical assessment, inclusive of the Symbol Digit Modalities Test and Unified Huntington's Disease Rating Scale Total Motor Score. Plasma NfL levels were measured using a Meso Scale Discovery assay.

resultsPre-HD and Man-HD cohorts differed by age (p < .0001), and CAG repeat number (p = .004), but not education level or gender. Plasma NfL levels were significantly correlated with PIN scores (r = 0.69, p < .0001) and PIN-YTO (r = -0.69, p < .0001). Plasma NfL levels were similarly correlated with predicted years to onset scores determined using Langbehn and colleague's formula (r = -0.68, p < .0001). All significant correlations endured corrections for age and CAG repeat number. A plasma NfL cut-point of <45.0 pg/ml distinguished Pre-HD participants >10 predicted years from Man-HD onset, compared to those ≤10 predicted years.

conclusionsWe have extensively shown that plasma NfL levels are associated with predicted years to manifest HD onset in Pre-HD participants, and present a plasma NfL cut-point that may help exclude far-from-onset Pre-HD patients from clinical trials.

Indexed as

Huntington DiseaseDisease ProgressionHumansIntermediate FilamentsNeurofilament ProteinsPrognosisNeurofilament ProteinsBiomarkerBloodHuntington's diseaseNeurofilament lightPlasma

Identifiers

PMID35276585
PMCPMC9127124
OpenAlexW4214811925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.